AMAG attributes increased second-quarter revenues of $18.

THE BUSINESS reported a net lack of $44.4 million, or a loss of $2.16 per basic and diluted share, for the six months ended June 30, 2010, when compared with a net lack of $52.9 million, or a loss of $3.10 per diluted and basic share, for the same period in ’09 2009.. AMAG attributes increased second-quarter revenues of $18.8 million to Feraheme AMAG Pharmaceuticals, Inc. , a biopharmaceutical organization focused on the advancement and commercialization of a therapeutic iron substance to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial outcomes for the second quarter and six months ended June 30, 2010.We do not plan to allow them down. We welcome this challenge, and of course plan to scale up our operations, as necessary, to continue to meet up our milestones and help validate this technology system. Soure: Advanced Cell Technology, Inc.. Intense vaccination effort reduces transmission of measles among North American Amish communities An aggressive vaccination work in response to the 2014 measles outbreak among UNITED STATES Amish communities in Ohio significantly reduced the transmission of measles and the expected number of instances, according to a new study, even though under-vaccination among the UNITED STATES Amish and in other communities around america resulted in the highest national annual number of reported situations in 2014 in the last 20 years.